Non-small cell lung cancer
Not yet recruitingPhase III Study of Izalontamab Brengitecan with Drug Combination versus Osimertinib Alone in First‑Line EGFR‑Mutated Advanced or Metastatic Non‑Small Cell Lung Cancer
Phase III Study of Izalontamab Brengitecan with Drug Combination versus Osimertinib Alone in First‑Line EGFR‑Mutated Advanced or Metastatic Non‑Small Cell Lung Cancer
- Disease:Non-small cell lung cancer
- Substances:CarboplatinCisplatin+4
Germany- Participants:18–64 years · 65+ years
- Substances:Carboplatin
- Sponsor:Bristol-Myers Squibb Services Unlimited Company












